Many factors must be considered when determining the best approach for development and manufacturing of a biopharmaceutical. The right strategy must align with organizational objectives, accelerate progress toward key milestones within regulatory expectations, and ensure quality and patient safety. Risk is always present and must be identified and weighed against the need to move quickly and remain compliant.
In many cases, a company will engage a contract development and manufacturing organization (CDMO). Outsourcing to an experienced CDMO can offer significant advantages in terms of speed, flexibility and risk mitigation. Use of an external partner can also reduce risk and provide flexibility when the timing of regulatory approval across multiple geographies is uncertain or delayed.
In this whitepaper, we share highlights from a global market research survey of small, mid-sized and large biopharmaceutical companies on trends related to outsourcing. Our experts then offer their perspectives on the survey results.